Laura Martelli1, Pablo Olivera1, Xavier Roblin2, Alain Attar3, Laurent Peyrin-Biroulet4. 1. Department of Hepato-Gastroenterology, University Hospital of Nancy, Université de Lorraine, Vandoeuvre-lès-Nancy, France. 2. Department of Gastroenterology, University Hospital of Saint Etienne, Saint-Étienne, France. 3. Department of Gastroenterology, IBD, Nutritional Support, Beaujon Hospital, Clichy, France. 4. Inserm U954 and Department of Hepato-Gastroenterology, University Hospital of Nancy-Brabois, université de Lorraine, Allée du Morvan, 54511, Vandoeuvre-lès-Nancy, France. peyrinbiroulet@gmail.com.
Abstract
BACKGROUND: Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The cost-effectiveness of this strategy is debated. METHODS: All studies comparing the cost-effectiveness of a TDM-based strategy and an empirical dose management of anti-TNF in IBD or RA were screened. Studies were identified through the MEDLINE electronic database (up to July 2016), and annual international meeting abstracts were also manually reviewed. RESULTS: Seven studies were included: two randomized controlled trials (RCTs) enrolling 332 patients [247 Crohn's disease (CD) and 85 ulcerative colitis (UC)] and five modeling approaches. Four studies included only CD patients, one included both CD and UC patients, and two included only RA patients. Three studies compared the cost-effectiveness of the two strategies in patients with secondary infliximab (IFX) failure (dose-escalation strategy), one in patients in remission on optimized IFX (de-escalation strategy), one in patients starting adalimumab, and two in patients with clinical response to maintenance anti-TNF therapy. The two RCTs demonstrated that a TDM strategy led to major cost savings, ranging from 28 to 34 %. The three modeling approaches with regard to CD patients demonstrated cost savings ranging from $5396 over a 1-year period to €13,130 per patient at 5 years of follow-up. A TDM strategy also led to major cost savings in the two modeling approaches in RA patients. CONCLUSIONS: Available evidence indicates that a TDM strategy leads to major cost savings related to anti-TNF therapy in both IBD and RA patients, with no negative impact on efficacy.
BACKGROUND: Therapeutic drug monitoring (TDM) of anti-TNF is increasingly used to manage inflammatory bowel diseases (IBD) and rheumatoid arthritis (RA). The cost-effectiveness of this strategy is debated. METHODS: All studies comparing the cost-effectiveness of a TDM-based strategy and an empirical dose management of anti-TNF in IBD or RA were screened. Studies were identified through the MEDLINE electronic database (up to July 2016), and annual international meeting abstracts were also manually reviewed. RESULTS: Seven studies were included: two randomized controlled trials (RCTs) enrolling 332 patients [247 Crohn's disease (CD) and 85 ulcerative colitis (UC)] and five modeling approaches. Four studies included only CDpatients, one included both CD and UC patients, and two included only RApatients. Three studies compared the cost-effectiveness of the two strategies in patients with secondary infliximab (IFX) failure (dose-escalation strategy), one in patients in remission on optimized IFX (de-escalation strategy), one in patients starting adalimumab, and two in patients with clinical response to maintenance anti-TNF therapy. The two RCTs demonstrated that a TDM strategy led to major cost savings, ranging from 28 to 34 %. The three modeling approaches with regard to CDpatients demonstrated cost savings ranging from $5396 over a 1-year period to €13,130 per patient at 5 years of follow-up. A TDM strategy also led to major cost savings in the two modeling approaches in RApatients. CONCLUSIONS: Available evidence indicates that a TDM strategy leads to major cost savings related to anti-TNF therapy in both IBD and RApatients, with no negative impact on efficacy.
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Casper Steenholdt; Jørn Brynskov; Ole Ø Thomsen; Lars K Munck; Jan Fallingborg; Lisbet A Christensen; Gitte Pedersen; Jens Kjeldsen; Bent A Jacobsen; Anne Sophie Oxholm; Jakob Kjellberg; Klaus Bendtzen; Mark A Ainsworth Journal: Dig Dis Sci Date: 2015-02-12 Impact factor: 3.199
Authors: Fernando S Velayos; James G Kahn; William J Sandborn; Brian G Feagan Journal: Clin Gastroenterol Hepatol Date: 2013-01-26 Impact factor: 11.382
Authors: C L M Krieckaert; S C Nair; M T Nurmohamed; C J J van Dongen; W F Lems; F P J G Lafeber; J W J Bijlsma; H Koffijberg; G Wolbink; P M J Welsing Journal: Ann Rheum Dis Date: 2013-11-21 Impact factor: 19.103
Authors: R N Maini; F C Breedveld; J R Kalden; J S Smolen; D Davis; J D Macfarlane; C Antoni; B Leeb; M J Elliott; J N Woody; T F Schaible; M Feldmann Journal: Arthritis Rheum Date: 1998-09
Authors: Freddy Cornillie; Stephen B Hanauer; Robert H Diamond; Jianping Wang; Kezhen L Tang; Zhenhua Xu; Paul Rutgeerts; Séverine Vermeire Journal: Gut Date: 2014-01-28 Impact factor: 23.059
Authors: Xavier Roblin; Alain Attar; Michel Lamure; Bernard Savarieau; Pierre Brunel; Gérard Duru; Laurent Peyrin-Biroulet Journal: J Mark Access Health Policy Date: 2015-10-30
Authors: N Vande Casteele; B G Feagan; S Vermeire; M Yassine; J Coarse; G Kosutic; W J Sandborn Journal: Aliment Pharmacol Ther Date: 2017-11-21 Impact factor: 8.171